



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_531_24

You asked:

Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

Six.

2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

None.

3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

- FCR (fludarabine + cyclophosphamide + rituximab)
- FR (fludarabine + rituximab)
- BR (bendamustine + rituximab)
- Bendamustine monotherapy
- RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
- Obinutuzumab ± chlorambucil
- Rituximab + chlorambucil
- Ofatumumab
- Other – please specify

Cadeirydd/Chair: Jonathan Morgan **Prif Weithredwr/Chief Executive:** Paul Mears

*Croeso i chi ohebu â'r bwrdd iechyd neu ein ffonio yn y Gymraeg neu'r Saesneg. Byddwn yn ymateb yn yr un iaith a ni fydd hyn yn arwain at oedi.
You are welcome to correspond with the Health Board or phone us in Welsh or English. We will respond accordingly and this will not delay the response.*

<https://ctmuhb.nhs.wales>

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Please see table below:

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	0
FR	0
BR	0
Bendamustine monotherapy	0
R-CHOP	0
Obinutuzumab ± chlorambucil	0
Rituximab + chlorambucil	0
Chlorambucil monotherapy	0
Rituximab monotherapy	0
Ofatumumab	0
Other – please specify	**
Alcalabrutinib	**
Obinutuzumab+venetoclax	**
Ibrutinib+venetoclax	

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low, we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.